Cancer is a Growing Worldwide Problem

Investment Opportunity

  • ST-001 nanoFenretinide, our first, patented drug candidate, represents a vast $2 Billion market potential.
  • ST-001 is based upon the safe drug fenretinide which is broadly applicable to several cancer types.
  • ST-001 will be an affordable treatment option.
  • ST-001 has a clear regulatory path with an accelerated clinical trial plan.
  • ST-001’s product development and manufacturing scale-up has been successfully completed.
  • We have the support of powerful institutions such as the National Cancer Institute (NCI) who is underwriting the supply of fenretinide for our clinical trials.
  • SciTech has several exit options and expansion strategies.
A chemist at work in a laboratory.
Scientists examining an image from an electron microscope.

How We’re Different

  • Quick Time to Market
  • Accelerated Phase 1 trial to confirm safety and demonstrate efficacy
  • Low cost of drug development
  • Low cost of outpatient administration
  • ST-001 is anticipated to have high efficacy and low toxicity (= high therapeutic index)
  • Multiple mechanisms of action to target a broad spectrum of cancers with no genetic markers required for use

Our Strategy

  • Our accelerated trial plan for ST-001 provides a rapid path to commercialization and revenue generation.
  • SciTech will continue to identify and develop additional drug candidates and administration routes to add to our product portfolio.
  • We seek companies that want to expand their existing drug portfolio in oncology, target new diseases, or develop combination drug therapies.
  • Potential exit strategies include licensing, partnerships, or a targeted acquisition.
Arrows hitting a bullseye.

Recent Milestones Achieved

ST-001 commercialization estimated 24 months or less after start of Phase 1a Trial

SciTech has made great strides over the last several years in our quest to bring ST-001 to market.

  • U.S. Small Business Innovation Research (SBIR) grants from the National Cancer Institute.
  • Investigational New Drug (IND) approval from the FDA, required to start clinical trials.
  • FDA guided clinical trial plan: Accelerated time to market and revenue generation.
  • FDA Orphan Drug Designation: Providing SciTech with exclusive marketing and development rights, federal tax credits and FDA fee reductions.
  • Multiple Institutional Review Board (IRB) approvals for initial clinical trials.

The Market Opportunity

SciTech's immediate and long-term market opportunity.

Questions about this investment opportunity?

Please contact David Schaffer for additional information.